Subscribe
shutterstock_281684060_mark_van_scyoc
Mark Van Scyoc / Shutterstock.com
18 November 2020AmericasRory O'Neill

Third Circuit under fire over FTC v AbbVie ruling

The US Federal Trade Commission and AbbVie both want a federal appeals court to rehear a lawsuit accusing the drug company of quashing competition through sham patent litigation.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Besins to pay FTC $448m in sham litigation case
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
AbbVie says bar for ‘sham litigation’ is too low
3 June 2021   AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.


Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024

Editor's picks

Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024
Americas
Amarin wins appeal to advance ‘skinny label’ suit over Hikma generic
27 June 2024
Biotechnology
Guardant Health files suit against Tempus AI
13 June 2024
Big Pharma
Roche fires lawsuit at Sinocare unit over blood glucose test strip patents
6 June 2024

More on this story

Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Besins to pay FTC $448m in sham litigation case
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
AbbVie says bar for ‘sham litigation’ is too low
3 June 2021   AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.

More on this story

Americas
FTC’s $448m AbbVie win overturned
2 October 2020   A US appeals court has cancelled a $448 million antitrust bill for AbbVie, in a blow for the US Federal Trade Commission.
Americas
AbbVie and Besins to pay FTC $448m in sham litigation case
2 July 2018   Pharmaceutical companies AbbVie and Besins Healthcare have been ordered to pay the US Federal Trade Commission $448 million for using “sham litigation” to block access to generic versions of a testosterone drug.
Americas
AbbVie says bar for ‘sham litigation’ is too low
3 June 2021   AbbVie has again urged the US Supreme Court to save it from claims of filing sham litigation to block competition for testosterone treatment AndroGel.

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB
Lewis Roca promotes tech expert to managing partner
Panitch Schwarze brings in molecular biologist
US targets ‘product hopping’ with biologic litigation curbs
UPC confirms validity of Edwards Lifesciences heart valve tech patent
ITC concludes row over biotech lab equipment between US and German rivals
UKIPO launches ‘revolutionary’ patent filing and AI tool
USPTO clarifies AI's role in patent eligibility